Estrogen insensitivity syndrome

A rare genetic condition affecting estrogen receptor function

Template:Medical condition (new)

Estrogen insensitivity syndrome (EIS) is a rare genetic disorder characterized by the body's inability to respond to estrogen, a key hormone in the development and regulation of the female reproductive system and secondary sexual characteristics. This condition is caused by mutations in the estrogen receptor gene, leading to a lack of response to estrogen despite normal or elevated levels of the hormone in the body.

Pathophysiology

Estrogen insensitivity syndrome is primarily caused by mutations in the ESR1 gene, which encodes the estrogen receptor alpha (ER_). This receptor is crucial for mediating the effects of estrogen in various tissues, including the breast, uterus, and bone. In individuals with EIS, mutations in the ESR1 gene result in a dysfunctional receptor that cannot bind estrogen effectively, leading to a lack of estrogenic action in target tissues.

Clinical Presentation

The clinical manifestations of estrogen insensitivity syndrome can vary widely, but common features include:

• Delayed puberty: Individuals with EIS often experience delayed or absent puberty, characterized by a lack of breast development and primary amenorrhea (absence of menstrual periods).
• Infertility: Due to the lack of estrogenic stimulation, affected individuals may have underdeveloped reproductive organs, leading to infertility.
• Osteoporosis: Estrogen plays a critical role in bone health, and its absence can lead to decreased bone density and increased risk of osteoporosis.
• Tall stature: Some individuals may exhibit tall stature due to delayed closure of the epiphyseal plates in bones.

Diagnosis

Diagnosis of estrogen insensitivity syndrome involves a combination of clinical evaluation, hormonal assays, and genetic testing. Key diagnostic steps include:

• Hormonal assays: Measurement of serum estrogen levels, which are typically normal or elevated, alongside low levels of estrogen-responsive proteins.
• Genetic testing: Identification of mutations in the ESR1 gene through DNA sequencing can confirm the diagnosis.

Management

There is currently no cure for estrogen insensitivity syndrome, and management focuses on addressing the symptoms and complications associated with the condition. Treatment options may include:

• Hormone replacement therapy: While traditional estrogen therapy is ineffective, other hormonal treatments may be considered to induce secondary sexual characteristics and manage bone health.
• Fertility treatment: Assisted reproductive technologies may be explored for individuals seeking to conceive.
• Bone health management: Calcium and vitamin D supplementation, along with other medications, may be used to prevent osteoporosis.

Prognosis

The prognosis for individuals with estrogen insensitivity syndrome varies depending on the severity of the condition and the effectiveness of symptom management. With appropriate medical care, many individuals can lead healthy lives, although challenges related to fertility and bone health may persist.

Related pages

• Estrogen receptor
• Hormone replacement therapy
• Genetic disorder
• Osteoporosis